Reduced cytotoxicity by mutation of lysine 590 of Pseudomonas exotoxin can be restored in an optimized, lysine-free immunotoxin. Issue 1 (21st February 2022)

• Record Type: Journal Article
• Authors: Ammon, A; Mellenthin, L; Emmerich, C; Naschberger, E; Stürzl, M; Mackensen, A; Müller, F
• Is Part Of: Immunotherapy advances. Volume 2:Issue 1(2022)
• Publication Date: 2022-02-21
• Subjects: immunotoxin -- antibody conjugate -- Pseudomonas exotoxin -- protein engineering -- lysine-free protein; Immunotherapy -- Periodicals; 615.37
• DOI: 10.1093/immadv/ltac007
• Languages: English
• ISSNs: 2732-4303

Abstract

Abstract: Immunotoxins, which are fusion proteins of an antibody fragment and a fragment of a bacterial or a plant toxin, induce apoptosis in target cells by inhibition of protein synthesis. ADP-ribosylating toxins often have few lysine residues in their catalytic domain. As they are the target for ubiquitination, the low number of lysines possibly prevents ubiquitin-dependent degradation of the toxin in the cytosol. To reduce this potential degradation, we aimed to generate a lysine-free (noK), Pseudomonas exotoxin (PE)-based immunotoxin. The new generation 24 kDa PE, which lacks all but the furin-cleavage site of domain II, was mutated at lysine 590 (K590) and at K606 in a CD22-targeting immunotoxin and activity was determined against various B cell malignancies in vitro and in vivo . On average, K590 mutated to arginine (R) reduced cytotoxicity by 1.3-fold and K606R enhanced cytotoxicity by 1.3-fold compared to wild type ( wt ). Mutating K590 to histidine or deleting K590 did not prevent this loss in cytotoxicity. Neither stability nor internalization rate of K590R could explain reduced cytotoxicity. These results highlight the relevance of lysine 590 for PE intoxication. In line with in vitro results, the K606R mutant was more than 1.8-fold more active than the other variants in vivo suggesting that this single mutation may be beneficial when targeting CD22-positive malignancies. Finally, reduced cytotoxicity by K590R was compensated for by K606R and the resulting lysine-free variant achieved wt -like activity in vitro and in vivo . Thus, PE24-noK may represent a promising candidate for down-stream applications that would interfere with lysines. Graphical Abstract: